LFG
ALNY icon

Larson Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Larson Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-900
Closed -$369 – 1793
2023
Q3 		$369 Buy
+900
New +$172K ﹤0.01% 1601

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Larson Financial Group's ALNY Position: Q1 2026 in Review

Larson Financial Group increased its Alnylam Pharmaceuticals (ALNY) stake by 35% in Q1 2026, buying an estimated $28.6K and bringing the position to 325 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #959.

Larson Financial Group first reported a position in ALNY in Q1 2024 and has held it in 9 quarters since. The position peaked at $137K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Larson Financial Group held 325 shares of Alnylam Pharmaceuticals worth $108K as of Q1 2026.
  • Larson Financial Group bought 84 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $28.6K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #959 holding.
  • Larson Financial Group first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Larson Financial Group's Alnylam Pharmaceuticals position peaked at $137K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.